FDA Database of Biologics: Navigating Regulatory Records

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-08-11

Introduction to the FDA Database of Biologics

What is the FDA Database of Biologics?

The FDA database of biologics is not a single monolithic repository but rather a constellation of interconnected regulatory databases maintained by the U.S. Food and Drug Administration's Center for Biologics Evaluation and Research (CBER) and Center for Drug Evaluation and Research (CDER). These databases collectively track the lifecycle of biological products—from investigational new drug (IND) applications through Biologics License Application (BLA) approval, post-market surveillance, and eventual discontinuation.

The primary components include the Purple Book (officially titled "Lists of Licensed Biological Products with Reference Product Exclusivity and Biosimilarity or Interchangeability Evaluations"), Drugs@FDA, the FDA Adverse Event Reporting System (FAERS), and the biologics section of the FDA's "Approved Products" database. Each serves a distinct function, yet together they form the authoritative record of what biologics are legally marketable in the United States, under what conditions, and with what regulatory history.

For a working scientist in the biotech industry, this database system is the definitive source for answering questions such as: Is this product approved? When was it approved? For what indications? What are the conditions of use? Is it a biosimilar or an interchangeable product? What adverse events have been reported? Understanding how to navigate these records efficiently is not a matter of convenience—it is a professional necessity for regulatory affairs, competitive intelligence, and clinical development planning.

Why Industry Scientists Need It

The FDA database of biologics serves as the ground truth for regulatory decision-making. When you are developing a biosimilar, you need to know the exact reference product characteristics, including its approved indications, dosing regimens, and the statutory exclusivity periods that govern when you can enter the market. When you are conducting competitive intelligence, you need to track not just current approvals but the complete supplement history—every change to manufacturing, labeling, or indication that the FDA has sanctioned. When you are assessing risk, you need access to adverse event reports that may reveal safety signals not apparent in clinical trial data.

Moreover, the database is essential for understanding the regulatory framework itself. The FDA Approval Process for Biologics is governed by the Public Health Service (PHS) Act Section 351, which requires that a biologic be shown to be "safe, pure, and potent" before licensure. The database operationalizes this statutory standard into searchable records that document how the FDA has interpreted these requirements across decades of approvals. For scientists who need to align their development programs with regulatory expectations, the database provides a historical record of what has been accepted—and rejected—in past applications.

Key Components of the Database

Approved Biologics and Licenses

The core of the FDA database of biologics is the listing of approved biological products, each associated with a specific BLA number. A BLA is the application submitted to the FDA requesting permission to introduce a biologic into interstate commerce. Unlike small-molecule drugs, which are approved under New Drug Applications (NDAs), biologics are licensed under the PHS Act, and this distinction matters for regulatory purposes.

Each BLA record contains the following essential data fields:

• BLA number: The unique identifier assigned to the application (e.g., BLA 103705 for rituximab)
• Proper name: The nonproprietary name assigned by the United States Adopted Names (USAN) Council
• Trade name: The proprietary brand name
• Applicant: The legal entity holding the license
• Approval date: The date the BLA was approved
• Indications: The specific diseases or conditions for which the product is approved
• Product class: The category of biologic (e.g., monoclonal antibody, recombinant protein, vaccine, allergenic, blood product)
• Manufacturing facility: The registered production sites

The database distinguishes between products regulated by CBER (vaccines, blood products, allergenic extracts, gene therapy, and cellular therapies) and those regulated by CDER (most monoclonal antibodies, recombinant proteins, and other therapeutic biologics). This division reflects historical regulatory assignments and is important for understanding which center's guidance and review standards apply to a given product.

Labels and Package Inserts

Every approved biologic has an associated FDA-approved labeling document—the package insert or Prescribing Information (PI). These labels are legally binding documents that define the conditions under which the product may be marketed. They contain critical information including:

• Indications and Usage: The approved clinical uses
• Dosage and Administration: Specific dosing regimens, including dose, frequency, route, and duration
• Contraindications: Situations where the product should not be used
• Warnings and Precautions: Serious safety concerns
• Adverse Reactions: Known side effects from clinical trials and post-market surveillance
• Use in Specific Populations: Pediatric, geriatric, pregnant, and renally/hepatically impaired patients
• Description: The molecular structure, mechanism of action, and formulation details

For a scientist developing a biosimilar, the reference product's label is the starting point for the "totality of the evidence" approach that the FDA uses to evaluate biosimilarity. The label defines the clinical context into which the biosimilar must fit, and the FDA requires that biosimilars receive their own label that may differ from the reference product's label in certain respects (e.g., the inclusion of biosimilarity data).

The database also contains the "recent major changes" sections that track labeling revisions, which are valuable for understanding how the FDA's understanding of a product's safety and efficacy profile has evolved over time.

Adverse Event Reporting System (FAERS)

The FDA Adverse Event Reporting System (FAERS) is the database that collects post-market safety reports for all approved drugs and biologics. For biologics, FAERS is supplemented by the Vaccine Adverse Event Reporting System (VAERS) for vaccines and the Manufacturer and User Facility Device Experience (MAUDE) database for devices used in conjunction with biologics.

FAERS contains individual case safety reports (ICSRs) that include:

• Patient demographics (age, sex, weight)
• Adverse event terms coded using the Medical Dictionary for Regulatory Activities (MedDRA)
• Suspect product(s) identified by name and NDC number
• Dose, route, and indication at the time of the event
• Outcome (death, life-threatening, hospitalization, disability, etc.)
• Reporter information (healthcare professional, consumer, manufacturer)

The FAERS database is searchable through the FDA's public dashboard, which allows users to query by product name, active ingredient, or MedDRA preferred term. However, it is critical to understand that FAERS is a passive surveillance system—it captures only reports that are voluntarily submitted by manufacturers, healthcare professionals, and consumers. It does not provide incidence rates, because the denominator (total number of patients exposed) is unknown. For a scientist conducting a safety assessment, FAERS data must be interpreted with this fundamental limitation in mind.

How to Access and Search the Database

Using the FDA Website

The primary access point for the FDA database of biologics is the FDA's website (fda.gov). The most useful entry points are:

1. Drugs@FDA: This searchable database contains information about both drugs and therapeutic biologics. It allows you to search by trade name, active ingredient, or application number. For each product, you can access the approval history, labels, review documents, and letters.

1. FDA Purple Book: This is the specific database for licensed biological products regulated by CDER and CBER. It includes all licensed biologics, including biosimilars and interchangeable products.

1. FAERS Public Dashboard: This interactive tool allows you to search adverse event reports using various filters.

1. OpenFDA: This is the FDA's application programming interface (API) that provides programmatic access to FDA data, including drug and biologic product labeling, adverse events, and recall information. For scientists who need to perform large-scale analyses, the OpenFDA API is the most efficient approach.

To search for a specific biologic, the most direct approach is to use the Drugs@FDA search function. Enter the trade name, proper name, or BLA number. For example, searching "trastuzumab" will return both the originator product (Herceptin, BLA 103792) and all approved biosimilars (e.g., Ogivri, BLA 761074). Each product page contains a comprehensive record of the approval history, including the original approval letter, all supplement approvals, and the current label.

Purple Book: Biosimilar and Interchangeable Products

The Purple Book is the authoritative source for determining the regulatory status of biological products with respect to biosimilarity and interchangeability. It is maintained in two sections: one for products regulated by CDER and one for products regulated by CBER.

The Purple Book provides the following information for each product:

• Product name (proper and trade names)
• BLA number
• Licensing date
• Reference product (for biosimilars)
• Biosimilarity determination (yes/no)
• Interchangeability determination (yes/no)
• Exclusivity expiration dates for reference products

The distinction between biosimilar and interchangeable is critical. A biosimilar is "highly similar" to the reference product with no clinically meaningful differences. An interchangeable product, in addition to meeting biosimilarity standards, is expected to produce the same clinical result as the reference product in any given patient, and can be substituted for the reference product without the intervention of the prescribing healthcare provider, subject to state pharmacy laws.

Search Tips and Filters

Effective searching of the FDA database of biologics requires an understanding of the search syntax and available filters:

• Use the BLA number: This is the most precise search term. If you know the BLA number, you can go directly to the product record.
• Use the proper name: Searching by the nonproprietary name (e.g., "adalimumab") will return all products containing that active ingredient, including the reference product and all biosimilars.
• Use the trade name: This will return a single product record.
• Filter by date: Drugs@FDA allows you to filter by approval date, which is useful for tracking recent approvals.
• Filter by regulatory center: If you are interested in vaccines or blood products, filter to CBER-regulated products.
• Use the "Application" tab: On each product page, the "Application" tab contains the approval history, including the original BLA and all supplements.

For programmatic access, the OpenFDA API supports queries such as https://api.fda.gov/drug/label.json?search=openfda.brand_name:"Herceptin" to retrieve labeling information in JSON format. This is particularly useful for building automated monitoring systems.

Understanding Regulatory Approval Records

BLA Approval History

The approval history of a biologic is documented in the Drugs@FDA database under the "Approval History, Letters, Reviews, and Related Documents" section. This section contains:

• The original approval letter: This document states the date of approval, the indications approved, and any conditions or post-marketing requirements.
• The approval package: This includes the FDA's review documents, which provide the scientific basis for the approval decision.
• The label at the time of approval: This is the original FDA-approved labeling.

The approval date is the date on which the FDA issued the approval letter. This date is significant for several reasons:

• It establishes the start of the reference product's exclusivity period (12 years from the date of first licensure under the Biologics Price Competition and Innovation Act of 2009).
• It determines the earliest date at which a biosimilar application can be submitted (4 years after licensure) and approved (12 years after licensure).
• It is used to calculate patent term restoration under the Hatch-Waxman Act, which applies to biologics through the Biologics Price Competition and Innovation Act.

For a scientist tracking the FDA Approved Biologics by Year, the approval date is the primary sorting criterion. The database allows you to generate lists of approvals by year, which is useful for understanding regulatory trends and the competitive landscape.

Supplement Approvals and Changes

After initial approval, biologics undergo changes that require FDA approval through supplement applications. The database tracks these supplements in the approval history. The main types of supplements are:

• Prior Approval Supplement (PAS): Required for changes that have a substantial potential to affect product safety or efficacy (e.g., changes in manufacturing process, formulation, or container closure system).
• Changes Being Effected (CBE): For changes with moderate potential to affect safety or efficacy, which can be implemented before FDA approval.
• Annual Report: For minor changes that do not require prior approval.

The supplement approval history is critical for understanding the current state of a product. For example, if a manufacturer has received approval for a supplement that changes the formulation from a lyophilized powder to a liquid solution, this information is in the database. The FDA Post Approval Changes Guidance Biologics provides detailed guidance on which changes require which type of supplement, and the database shows how these requirements have been applied in practice.

Pediatric Exclusivity and Orphan Drug Status

The FDA database of biologics also records special regulatory designations that affect market exclusivity:

• Pediatric Exclusivity: Under the Best Pharmaceuticals for Children Act, a biologic can receive an additional 6 months of exclusivity if the sponsor conducts FDA-requested pediatric studies. This is recorded in the database and extends all exclusivity periods, including the 12-year biologic exclusivity.
• Orphan Drug Designation: Under the Orphan Drug Act, a biologic designated for a rare disease (affecting fewer than 200,000 patients in the U.S.) receives 7 years of market exclusivity from the date of approval. The database records orphan drug designations and approvals.
• Pediatric Rare Disease Priority Review Voucher: This program provides a transferable voucher for priority review of a future application, awarded for approval of a biologic for a rare pediatric disease.

These designations are important for competitive intelligence because they affect the timing of market entry for biosimilars and follow-on products. The database allows you to search for products with orphan drug designation and to see the exclusivity expiration dates.

Biosimilars and Interchangeability in the Database

Purple Book Listings

The Purple Book is the definitive source for biosimilar and interchangeable product listings. Each biosimilar entry includes:

• The reference product: The biologic against which the biosimilar was evaluated
• The date of licensure: When the biosimilar was approved
• The biosimilarity determination: Confirmation that the product meets the statutory standard for biosimilarity
• The interchangeability determination: Whether the product has been granted interchangeable status

For example, the Purple Book lists adalimumab-atto (Amjevita) as a biosimilar to Humira (adalimumab), with a licensure date of September 23, 2016. It also lists adalimumab-adbm (Cyltezo) as the first interchangeable adalimumab product, with an interchangeability determination date of October 15, 2021.

Interchangeability Designations

Interchangeability is a higher standard than biosimilarity. To receive an interchangeability designation, the sponsor must demonstrate that the product is biosimilar to the reference product and that it can be expected to produce the same clinical result as the reference product in any given patient. Additionally, for products administered more than once, the sponsor must demonstrate that the risk in terms of safety or diminished efficacy of alternating or switching between the biosimilar and the reference product is not greater than the risk of using the reference product without such alternation or switching.

The database records the interchangeability determination date, which is distinct from the licensure date. As of 2025, only a small number of biologics have received interchangeability designations, including:

• Insulin glargine-yfgn (Semglee) — interchangeable with Lantus
• Adalimumab-adbm (Cyltezo) — interchangeable with Humira
• Etanercept-ykro (Erelzi) — biosimilar but not interchangeable with Enbrel

The distinction matters for market access because interchangeable products can be substituted at the pharmacy level without prescriber involvement, subject to state laws.

Comparing Biosimilar and Reference Product Records

When comparing a biosimilar to its reference product in the database, pay attention to the following fields:

The database also shows whether the biosimilar received extrapolation of indications—that is, whether it was approved for indications held by the reference product without conducting separate clinical trials for each indication. This is a key scientific and regulatory decision that is documented in the FDA review documents.

Using the Database for Competitive Intelligence

Tracking Competitor Approvals

The FDA database of biologics is an essential tool for tracking competitor activity. By monitoring new BLA approvals, you can identify when a competitor's product enters the market. The database allows you to:

• Set up alerts: The FDA offers email alerts for new approvals, which can be customized by product category.
• Monitor supplement approvals: When a competitor receives approval for a new indication or a manufacturing change, this is recorded in the database.
• Track pediatric exclusivity: When a competitor receives pediatric exclusivity, this extends their market protection by 6 months.

For example, if you are developing a biosimilar to a reference product, you should monitor the reference product's exclusivity expiration date, which is listed in the Purple Book. The Biologics License Application FDA process requires that a biosimilar application be submitted no earlier than 4 years after the reference product's licensure date, and the FDA cannot approve the application until 12 years after licensure.

Identifying Expiring Exclusivities

The database is the primary source for identifying when exclusivities expire, which is critical for planning market entry. The key exclusivity periods to track are:

• 12-year biologic exclusivity: From the date of first licensure of the reference product
• 6-month pediatric exclusivity: Added to the 12-year period if pediatric studies are completed
• 7-year orphan drug exclusivity: From the date of approval for orphan-designated products
• Patent term restoration: Up to 5 years added to patent terms to compensate for regulatory review time

The Purple Book lists the exclusivity expiration dates for reference products, which provides a clear timeline for when biosimilar entry becomes possible. However, it is important to note that the database does not provide patent information—patent litigation is handled separately through the patent dance provisions of the Biologics Price Competition and Innovation Act.

Monitoring Post-Market Changes

Post-market changes can have significant implications for competitive intelligence. The database tracks:

• Safety-related labeling changes: When the FDA requires a label change due to new safety information, this is documented.
• Manufacturing changes: When a manufacturer changes its production process, this may affect product quality and supply.
• Market withdrawals: When a product is discontinued, this is recorded, although the database may not always be timely in reflecting this.

For a scientist in the industry, monitoring these changes is essential for understanding the competitive landscape. A competitor's manufacturing change could lead to supply disruptions, creating opportunities for your product. Conversely, a safety signal could lead to restrictions that affect the entire product class.

Limitations and Common Pitfalls

Incomplete Historical Data

The FDA database of biologics is not complete for all historical products. While the database includes products approved since the 1980s, some older products may have incomplete records. For example, some blood products and vaccines that were licensed under earlier regulatory frameworks may not have full electronic records in Drugs@FDA. If you need historical data on such products, you may need to consult the FDA's paper archives or request records through the Freedom of Information Act (FOIA).

Additionally, the database does not include all investigational products. Products that were never approved or that failed in clinical trials are not listed, which means the database cannot be used to assess the full pipeline of failed candidates.

Delayed Updates

The FDA database is updated regularly, but there can be delays between a regulatory action and its appearance in the database. For example, a supplement approval may take several weeks to appear in the approval history. Similarly, the Purple Book may not be updated immediately when a new biosimilar is approved.

For time-sensitive decisions, it is advisable to cross-reference the database with the FDA's press releases and the Federal Register, which publish regulatory actions more promptly. The FDA Guidance for Industry Biologics documents often reference the database, and these guidance documents are updated more frequently than the database itself.

Misreading Approval vs. Marketing Status

A common pitfall is confusing approval status with marketing status. A product can be approved by the FDA but not actually marketed in the United States. This can occur for several reasons:

• Commercial decisions: The sponsor may choose not to launch the product for business reasons.
• Supply constraints: Manufacturing issues may delay market entry.
• Patent litigation: The sponsor may be enjoined from marketing the product due to patent infringement.

The FDA database records approval status but does not reliably track marketing status. To determine whether a product is actually on the market, you may need to consult commercial databases (e.g., IQVIA) or check the FDA's drug shortage list.

Another related pitfall is assuming that a product is available in all approved indications. The FDA may approve a product for multiple indications, but the sponsor may choose to market the product only for a subset of those indications. The database does not track which indications are actively marketed.

Practical Summary: Best Practices for Industry Scientists

Quick Reference Workflow

For efficient use of the FDA database of biologics, follow this workflow:

1. Identify the product: Determine the proper name, trade name, or BLA number.
2. Search Drugs@FDA: Use the product name or BLA number to access the product record.
3. Review the approval history: Check the original approval date and all supplement approvals.
4. Download the current label: This is the authoritative source for indications, dosing, and safety information.
5. Check the Purple Book: Determine biosimilar/interchangeable status and exclusivity expiration dates.
6. Search FAERS: If you need safety data, query the FAERS dashboard for adverse event reports.
7. Cross-reference with other sources: Verify findings with the FDA's press releases, Federal Register notices, and commercial databases.

Cross-Referencing with Other FDA Databases

The FDA database of biologics should not be used in isolation. Cross-referencing with other FDA databases provides a more complete picture:

• FDA Recall Database: Check for recalls of the product.
• FDA Drug Shortage Database: Determine if the product is in shortage.
• FDA Inspection Database: Check the compliance status of manufacturing facilities.
• ClinicalTrials.gov: Review ongoing clinical trials for the product.

The Biologics Regulatory Affairs Course materials emphasize the importance of this cross-referencing approach, as each database provides a different perspective on the product's regulatory status.

Staying Updated with FDA Alerts

The FDA offers several mechanisms for staying updated on regulatory actions:

• FDA-L email lists: Subscribe to receive press releases and regulatory announcements.
• RSS feeds: The FDA provides RSS feeds for new approvals and safety alerts.
• Purple Book updates: The FDA publishes periodic updates to the Purple Book, which can be downloaded as a spreadsheet.
• OpenFDA API: For automated monitoring, the OpenFDA API can be queried programmatically.

For scientists who need to track multiple products, setting up automated alerts through the OpenFDA API is the most efficient approach. The API allows you to query for new approvals, labeling changes, and adverse events on a scheduled basis.

Frequently Asked Questions

How do I find the approval date for a biologic in the FDA database?

Search for the product in Drugs@FDA using the trade name, proper name, or BLA number. On the product page, click the "Approval History, Letters, Reviews, and Related Documents" tab. The original approval date is listed at the top of this section, along with the approval letter. The approval date is also listed in the Purple Book for all licensed biologics.

What is the difference between the Purple Book and Drugs@FDA?

The Purple Book is specifically for licensed biological products and provides information on biosimilarity, interchangeability, and exclusivity expiration dates. Drugs@FDA is a broader database that includes both small-molecule drugs and therapeutic biologics, and it provides more detailed approval history, review documents, and labeling information. For a complete picture, you should consult both databases.

Can I search the FDA database for adverse event reports for a specific biologic?

Yes. The FAERS Public Dashboard allows you to search adverse event reports by product name, active ingredient, or BLA number. You can filter by date, outcome, and reporter type. For vaccines, use the VAERS database instead. Note that FAERS is a passive surveillance system, so the data should be interpreted with caution—it captures reports but not incidence rates.

How often is the FDA database of biologics updated?

Drugs@FDA is updated daily, but individual product records may not reflect regulatory actions immediately. The Purple Book is updated periodically, typically on a monthly basis. FAERS is updated quarterly for the public dashboard, although the underlying data is submitted continuously. For the most current information, cross-reference with FDA press releases and Federal Register notices.

Does the FDA database include biologics that are no longer marketed?

Yes, the database includes products that have been approved but are no longer marketed. However, the database does not reliably indicate marketing status. A product may be approved but not marketed due to commercial decisions, supply constraints, or patent litigation. To determine marketing status, consult commercial databases or the FDA's drug shortage list.

How can I tell if a biologic is biosimilar or interchangeable in the database?

The Purple Book is the authoritative source for this information. Each product entry indicates whether it is a reference product, a biosimilar, or an interchangeable product. For biosimilars, the Purple Book lists the reference product and the date of licensure. For interchangeable products, it lists the interchangeability determination date.

Are there any fees to access the FDA database of biologics?

No. All FDA databases, including Drugs@FDA, the Purple Book, FAERS, and the OpenFDA API, are freely accessible to the public. There is no charge for searching or downloading data. However, if you need to request records through FOIA that are not available in the public databases, there may be processing fees.

Key Takeaways

• The FDA database of biologics is a collection of interconnected databases—Drugs@FDA, the Purple Book, FAERS, and OpenFDA—that together provide the complete regulatory record for biological products.
• The BLA number is the most precise identifier for searching; use it in conjunction with the proper name and trade name for comprehensive results.
• The Purple Book is the definitive source for biosimilar and interchangeability determinations, as well as exclusivity expiration dates for reference products.
• Approval status does not equal marketing status; always cross-reference with commercial databases and the FDA's shortage list to determine actual market availability.
• FAERS data must be interpreted with the understanding that it is a passive surveillance system—it provides signal detection, not incidence rates.
• For competitive intelligence, monitor supplement approvals, pediatric exclusivity extensions, and orphan drug designations, as these affect market entry timing.
• The OpenFDA API is the most efficient tool for automated monitoring of regulatory actions, enabling programmatic queries for new approvals, labeling changes, and adverse events.

Related Clinical & Scientific Guides

• MAPK Pathway: Mechanism, Function, and Clinical Relevance
• Mammalian Cell Culture Bioreactors: A Practical Guide
• Nucleotide Formation: Biosynthesis and Assembly of DNA/RNA Building Blocks